Comprehensive analysis of a novel mouse model of the 22q11.2 deletion syndrome: a model with the most common 3.0-Mb deletion at the human 22q11.2 locus.


Journal

Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664

Informations de publication

Date de publication:
05 02 2020
Historique:
received: 05 06 2019
accepted: 10 01 2020
revised: 03 01 2020
entrez: 19 2 2020
pubmed: 19 2 2020
medline: 22 6 2021
Statut: epublish

Résumé

The 22q11.2 deletion syndrome (22q11.2DS) is associated with an increased risk for psychiatric disorders. Although most of the 22q11.2DS patients have a 3.0-Mb deletion, existing mouse models only mimic a minor mutation of 22q11.2DS, a 1.5-Mb deletion. The role of the genes existing outside the 1.5-Mb deletion in psychiatric symptoms of 22q11.2DS is unclear. In this study, we generated a mouse model that reproduced the 3.0-Mb deletion of the 22q11.2DS (Del(3.0 Mb)/ +) using the CRISPR/Cas9 system. Ethological and physiological phenotypes of adult male mutants were comprehensively evaluated by visual-evoked potentials, circadian behavioral rhythm, and a series of behavioral tests, such as measurement of locomotor activity, prepulse inhibition, fear-conditioning memory, and visual discrimination learning. As a result, Del(3.0 Mb)/ + mice showed reduction of auditory prepulse inhibition and attenuated cue-dependent fear memory, which is consistent with the phenotypes of existing 22q11.2DS models. In addition, Del(3.0 Mb)/ + mice displayed an impaired early visual processing that is commonly seen in patients with schizophrenia. Meanwhile, unlike the existing models, Del(3.0 Mb)/ + mice exhibited hypoactivity over several behavioral tests, possibly reflecting the fatigability of 22q11.2DS patients. Lastly, Del(3.0 Mb)/ + mice displayed a faster adaptation to experimental jet lag as compared with wild-type mice. Our results support the validity of Del(3.0 Mb)/ + mice as a schizophrenia animal model and suggest that our mouse model is a useful resource to understand pathogenic mechanisms of schizophrenia and other psychiatric disorders associated with 22q11.2DS.

Identifiants

pubmed: 32066675
doi: 10.1038/s41398-020-0723-z
pii: 10.1038/s41398-020-0723-z
pmc: PMC7026107
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

35

Subventions

Organisme : Japan Agency for Medical Research and Development (AMED)
ID : 18dm0207004h0005
Pays : International
Organisme : Japan Agency for Medical Research and Development (AMED)
ID : 18dm0207004h0005
Pays : International
Organisme : Japan Agency for Medical Research and Development (AMED)
ID : 18dm0207004h0005
Pays : International
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 17H06096
Pays : International
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 17H06096
Pays : International
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 17H06096
Pays : International

Références

Devriendt, K., Fryns, J. P., Mortier, G., van Thienen, M. N. & Keymolen, K. The annual incidence of DiGeorge/velocardiofacial syndrome. J. Med. Genet. 35, 789–790 (1998).
pubmed: 9733045 pmcid: 1051442 doi: 10.1136/jmg.35.9.789-a
Bassett, A. S. et al. Clinical features of 78 adults with 22q11 deletion syndrome. Am. J. Med. Genet. A. 138, 307–313 (2005).
pubmed: 16208694 pmcid: 3127862 doi: 10.1002/ajmg.a.30984
Gothelf, D. et al. Obsessive-compulsive disorder in patients with velocardiofacial (22q11 deletion) syndrome. Am. J. Med. Genet. B Neuropsychiatr. Genet. 126, 99–105 (2004).
doi: 10.1002/ajmg.b.20124
Niklasson, L., Rasmussen, P., Oskarsdottir, S. & Gillberg, C. Autism, ADHD, mental retardation and behavior problems in 100 individuals with 22q11 deletion syndrome. Res. Dev. Disabil. 30, 763–773 (2009).
pubmed: 19070990 doi: 10.1016/j.ridd.2008.10.007
Mok, K. Y. et al. Deletions at 22q11.2 in idiopathic Parkinson’s disease: a combined analysis of genome-wide association data. Lancet Neurol. 15, 585–596 (2016).
pubmed: 27017469 pmcid: 4828586 doi: 10.1016/S1474-4422(16)00071-5
Buckley, E., Siddique, A. & McNeill, A. Hyposmia, symptoms of rapid eye movement sleep behavior disorder, and parkinsonian motor signs suggest prodromal neurodegeneration in 22q11 deletion syndrome. Neuroreport 28, 677–681 (2017).
pubmed: 28574926 doi: 10.1097/WNR.0000000000000815
Kirov, G. et al. The penetrance of copy number variations for schizophrenia and developmental delay. Biol. Psychiatry 75, 378–385 (2014).
pubmed: 23992924 doi: 10.1016/j.biopsych.2013.07.022
Grozeva, D. et al. Independent estimation of the frequency of rare CNVs in the UK population confirms their role in schizophrenia. Schizophr. Res. 135, 1–7 (2012).
pubmed: 22130109 pmcid: 3315675 doi: 10.1016/j.schres.2011.11.004
Szatkiewicz, J. et al. Copy number variation in schizophrenia in Sweden. Mol. Psychiatry 19, 762–773 (2014).
pubmed: 24776740 pmcid: 4271733 doi: 10.1038/mp.2014.40
The International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 455, 237–241 (2008).
pmcid: 3912847 doi: 10.1038/nature07239
Michaelovsky, E. et al. Genotype-phenotype correlation in 22q11.2 deletion syndrome. BMC Med. Genet. 13, 122 (2012).
pubmed: 23245648 pmcid: 3548696 doi: 10.1186/1471-2350-13-122
Carlson, C. et al. Molecular definition of 22q11 deletions in 151 velo-cardio-facial syndrome patients. Am. J. Hum. Genet. 61, 620–629 (1997).
pubmed: 9326327 pmcid: 1715959 doi: 10.1086/515508
Guo, T. W. et al. Deletion size analysis of 1680 22q11.2DS subjects identifies a new recombination hotspot on chromosome 22q11.2. Hum. Mol. Genet. 27, 1150–1163 (2008).
doi: 10.1093/hmg/ddy028
Emanuel, B. S. Molecular mechanisms and diagnosis of chromosome 22q11.2 rearrangements. Dev. Disabil. Res. Rev. 14, 11–18 (2008).
pubmed: 18636632 pmcid: 2810965 doi: 10.1002/ddrr.3
Kushima, I. et al. Comparative analyses of copy-number variation in autism spectrum disorder and schizophrenia reveal etiological overlap and biological insights. Cell Rep. 24, 2838–2856 (2018).
pubmed: 30208311 doi: 10.1016/j.celrep.2018.08.022
Lindsay, E. A. et al. Congenital heart disease in mice deficient for the DiGeorge syndrome region. Nature 401, 379–383 (1999).
pubmed: 10517636
Merscher, S. et al. TBX1 is responsible for cardiovascular defects in velo-cardio-facial/DiGeorge syndrome. Cell 104, 619–629 (2001).
pubmed: 11239417 doi: 10.1016/S0092-8674(01)00247-1
Stark, K. L. et al. Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. Nat. Genet. 40, 751–760 (2008).
pubmed: 18469815 doi: 10.1038/ng.138
Nilsson, S. R. et al. Assessing the cognitive translational potential of a mouse model of the 22q11.2 microdeletion syndrome. Cereb. Cortex. 26, 3991–4003 (2016).
pubmed: 27507786 pmcid: 5028007 doi: 10.1093/cercor/bhw229
Forsingdal, A. et al. Can animal models of copy number variants that predispose to schizophrenia elucidate underlying biology? Biol. Psychiatry 85, 13–24 (2019).
pubmed: 30144930 doi: 10.1016/j.biopsych.2018.07.004
Boroviak, K., Doe, B., Banerjee, R., Yang, F. & Bradley, A. Chromosome engineering in zygotes with CRISPR/Cas9. Genesis 54, 78–85 (2016).
pubmed: 26742453 pmcid: 4819711 doi: 10.1002/dvg.22915
Hamm, J. P. & Yuste, R. Somatostatin interneurons control a key component of mismatch negativity in mouse visual cortex. Cell Rep. 16, 597–604 (2016).
pubmed: 27396334 pmcid: 4956574 doi: 10.1016/j.celrep.2016.06.037
Triboulet, R., Chang, H. M., Lapierre, R. J. & Gregory, R. I. Post-transcriptional control of DGCR8 expression by the Microprocessor. RNA 15, 1005–1011 (2009).
pubmed: 19383765 pmcid: 2685516 doi: 10.1261/rna.1591709
Goldberg, R., Motzkin, B., Marion, R., Scambler, P. J. & Shprintzen, R. J. Velo-cardio-facial syndrome: a review of 120 patients. Am. J. Med. Genet. 45, 313–319 (1993).
pubmed: 8434617 doi: 10.1002/ajmg.1320450307
Ryan, A. K. et al. Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study. J. Med. Genet. 34, 798–804 (1997).
pubmed: 9350810 pmcid: 1051084 doi: 10.1136/jmg.34.10.798
Muller, W. et al. The DiGeorge syndrome. 1. clinical evaluation and course of partial and complete forms of the syndrome. Eur. J. Pediatr. 147, 496–502 (1988).
pubmed: 3044796 doi: 10.1007/BF00441974
Markert, M. L. et al. Complete DiGeorge syndrome: persistence of profound immunodeficiency. J. Pediatr. 132, 15–21 (1998).
pubmed: 9469994 doi: 10.1016/S0022-3476(98)70478-0
Braff, D. L., Swerdlow, N. R. & Geyer, M. A. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am. J. Psychiatry 156, 596–602 (1999).
pubmed: 10200740
Grillon, C., Ameli, R., Charney, D. S., Krystal, J. & Braff, D. Startle gating deficits occur across prepulse intensities in schizophrenic-patients. Biol. Psychiatry 32, 939–943 (1992).
pubmed: 1467378 doi: 10.1016/0006-3223(92)90183-Z
Parwani, A. et al. Impaired prepulse inhibition of acoustic startle in schizophrenia. Biol. Psychiatry 47, 662–669 (2000).
pubmed: 10745060 doi: 10.1016/S0006-3223(99)00148-1
Moriwaki, M. et al. Prepulse inhibition of the startle response with chronic schizophrenia: a replication study. Neurosci. Res. 65, 259–262 (2009).
pubmed: 19660506 doi: 10.1016/j.neures.2009.07.009
Campeau, S. & Davis, M. Prepulse inhibition of the acoustic startle reflex using visual and auditory prepulse: disruption by apomorphine. Psychopharmacology 117, 267–274 (1995).
pubmed: 7770602 doi: 10.1007/BF02246101
Young, J. W., Wallace, C. K., Geyer, M. A. & Risbrough, V. B. Age-associated improvements in cross-modal prepulse inhibition in mice. Behav. Neurosci. 124, 133–140 (2010).
pubmed: 20141288 pmcid: 3088993 doi: 10.1037/a0018462
Piskorowski, R. A. et al. Age-dependent specific changes in area CA2 of the hippocampus and social memory deficit in a mouse model of the 22q11.2 deletion syndrome. Neuron 89, 163–176 (2016).
pubmed: 26748091 pmcid: 4706988 doi: 10.1016/j.neuron.2015.11.036
Diamantopoulou, A. et al. Loss-of-function mutation in Mirta22/Emc10 rescues specific schizophrenia-related phenotypes in a mouse model of the 22q11.2 deletion. Proc. Natl Acad. Sci. USA 114, e6127–e6136 (2017).
pubmed: 28696314 pmcid: 5544257 doi: 10.1073/pnas.1615719114
Lascano, A. M., Lalive, P. H., Hardmeier, M., Fuhr, P. & Seeck, M. Clinical evoked potentials in neurology: a review of techniques and indications. J. Neurol. Neurosurg. Psychiatry 88, 688–696 (2017).
pubmed: 28235778 doi: 10.1136/jnnp-2016-314791
Heike, C. L. et al. Sleep disturbances in 22q11.2 deletion syndrome: a case with obstructive and central sleep apnea. Cleft Palate Craniofac. J. 44, 340–346 (2007).
pubmed: 17477750 doi: 10.1597/05-196
Crockett, D. J., Goudy, S. L., Chinnadurai, S. & Wootten, C. T. Obstructive sleep apnea syndrome in children with 22q11.2 deletion syndrome after operative intervention for velopharyngeal insufficiency. Front. Pediatr. 2, 84 (2014).
pubmed: 25157342 pmcid: 4127662 doi: 10.3389/fped.2014.00084
Kennedy, W. P. et al. 22q11.2 Deletion syndrome and obstructive sleep apnea. Int. J. Pediatr. Otorhinolaryngol. 78, 1360–1364 (2014).
pubmed: 24958162 doi: 10.1016/j.ijporl.2014.05.031
Sutton, E. L. Psychiatric disorders and sleep issues. Med. Clin. North Am. 98, 1123–1143 (2014).
pubmed: 25134876 doi: 10.1016/j.mcna.2014.06.009
Charrier, A., Olliac, B., Roubertoux, P. & Tordjman, S. Clock genes and altered sleep-wake rhythms: their role in the development of psychiatric disorders. Int. J. Mol. Sci. 18, e938 (2017).
pubmed: 28468274 doi: 10.3390/ijms18050938
Kon, N. et al. CaMKII is essential for the cellular clock and coupling between morning and evening behavioral rhythms. Genes. Dev. 28, 1101–1110 (2014).
pubmed: 24831701 pmcid: 4035538 doi: 10.1101/gad.237511.114
Lindsay, E. A. et al. Tbx1 haploinsufficiency in the DiGeorge syndrome region causes aortic arch defects in mice. Nature 410, 97–101 (2001).
pubmed: 11242049 doi: 10.1038/35065105
Hiroi, N. & Yamauchi, T. Modeling and predicting developmental trajectories of neuropsychiatric dimensions associated with copy number variations. Int. J. Neuropsychopharmacol. 22, 488–500 (2019).
pubmed: 31135887 pmcid: 6672556 doi: 10.1093/ijnp/pyz026
Marissal, T. et al. Restoring wild-type-like CA1 network dynamics and behavior during adulthood in a mouse model of schizophrenia. Nat. Neurosci. 21, 1412–1420 (2018).
pubmed: 30224804 pmcid: 6978142 doi: 10.1038/s41593-018-0225-y
Vergaelen, E., Claes, S., Kempke, S. & Swillen, A. High prevalence of fatigue in adults with a 22q11.2 deletion syndrome. Am. J. Med. Genet. A. 173, 858–867 (2017).
pubmed: 28190295 doi: 10.1002/ajmg.a.38094
Campbell, L. et al. Visual scanning of faces in 22q11.2 deletion syndrome: attention to the mouth or the eyes? Psychiatr. Res. 177, 211–215 (2010).
doi: 10.1016/j.psychres.2009.06.007
Campbell, L. E. et al. Is theory of mind related to social dysfunction and emotional problems in 22q11.2 deletion syndrome (velo-cardio-facial syndrome)? J. Neurodev. Disord. 3, 152–161 (2011).
pubmed: 21544568 pmcid: 3188292 doi: 10.1007/s11689-011-9082-7
Shashi, V. et al. Social skills and associated psychopathology in children with chromosome 22q11.2 deletion syndrome: implications for interventions. J. Intellect. Disabil. Res. 56, 865–878 (2012).
pubmed: 21883601 doi: 10.1111/j.1365-2788.2011.01477.x
Jalbrzikowski, M. et al. Social cognition in 22q11.2 microdeletion syndrome: relevance to psychosis? Schizophr. Res. 142, 99–107 (2012).
pubmed: 23122739 pmcid: 3714207 doi: 10.1016/j.schres.2012.10.007
Gur, R. E. et al. Neurocognitive development in 22q11.2 deletion syndrome: comparison with youth having developmental delay and medical comorbidities. Mol. Psychiatry 19, 1205–1211 (2014).
pubmed: 24445907 pmcid: 4450860 doi: 10.1038/mp.2013.189
Badoud, D. et al. Understanding others: a pilot investigation of cognitive and affective facets of social cognition in patients with 22q11.2 deletion syndrome (22q11DS). J. Neurodev. Disord. 9, 35 (2017).
pubmed: 28946869 pmcid: 5613394 doi: 10.1186/s11689-017-9216-7
Reyes, M. R., LeBlanc, E. M. & Bassila, M. K. Hearing loss and otitis media in velo-cardio-facial syndrome. Int. J. Pediatr. Otorhinolaryngol. 47, 227–233 (1999).
pubmed: 10321777 doi: 10.1016/S0165-5876(98)00180-3
Fuchs, J. C. et al. Hearing loss in a mouse model of 22q11.2 deletion syndrome. PLoS ONE 8, e80104 (2013).
pubmed: 24244619 pmcid: 3828191 doi: 10.1371/journal.pone.0080104
Csomor, P. A. et al. On the influence of baseline startle reactivity on the indexation of prepulse inhibition. Behav. Neurosci. 122, 885–900 (2008).
pubmed: 18729642 doi: 10.1037/0735-7044.122.4.885
Yee, B. K., Chang, T., Pietropaolo, S. & Feldon, J. The expression of prepulse inhibition of the acoustic startle reflex as a function of three pulse stimulus intensities, three prepulse stimulus intensities, and three levels of startle responsiveness in C57BL6/J mice. Behav. Brain Res. 163, 265–276 (2005).
pubmed: 16039728 doi: 10.1016/j.bbr.2005.05.013
Shoji, H. & Miyakawa, T. Relationships between the acoustic startle response and prepulse inhibition in C57BL/6J mice: a large-scale meta-analytic study. Mol. Brain 11, 42 (2008).
doi: 10.1186/s13041-018-0382-7
Vaiceliunaite, A., Erisken, S., Franzen, F., Katzner, S. & Busse, L. Spatial integration in mouse primary visual cortex. J. Neurophysiol. 110, 964–972 (2013).
pubmed: 23719206 pmcid: 3742980 doi: 10.1152/jn.00138.2013
Chun, S. et al. Specific disruption of thalamic inputs to the auditory cortex in schizophrenia models. Science 344, 1178–1182 (2014).
pubmed: 24904170 pmcid: 4349506 doi: 10.1126/science.1253895
Butler, P. D. et al. Dysfunction of early-stage visual processing in schizophrenia. Am. J. Psychiatry 158, 1126–1133 (2001).
pubmed: 11431235 doi: 10.1176/appi.ajp.158.7.1126
Foxe, J. J., Doniger, G. M. & Javitt, D. C. Early visual, processing deficits in schizophrenia: impaired P1 generation revealed by high-density electrical mapping. Neuroreport 12, 3815–3820 (2001).
pubmed: 11726801 doi: 10.1097/00001756-200112040-00043
Doniger, G. M., Foxe, J. J., Murray, M. M., Higgins, B. A. & Javitt, D. C. Impaired visual object recognition and Dorsal/Ventral stream interaction in schizophrenia. Arch. Gen. Psychiatry 59, 1011–1020 (2002).
pubmed: 12418934 doi: 10.1001/archpsyc.59.11.1011
Foxe, J. J., Murray, M. M. & Javitt, D. C. Filling-in in schizophrenia: a high-density electrical mapping and source-analysis investigation of illusory contour processing. Cereb. Cortex 15, 1914–1927 (2005).
pubmed: 15772373 doi: 10.1093/cercor/bhi069
Butler, P. D. et al. Subcortical visual dysfunction in schizophrenia drives secondary cortical impairments. Brain 130, 417–430 (2007).
pubmed: 16984902 doi: 10.1093/brain/awl233
Knebel, J. F., Javitt, D. C. & Murray, M. M. Impaired early visual response modulations to spatial information in chronic schizophrenia. Psychiatry Res. Neuroimaging. 193, 168–176 (2011).
doi: 10.1016/j.pscychresns.2011.02.006
Biria, M. et al. Visual processing deficits in 22q11.2 deletion syndrome. Neuroimage Clin. 17, 976–986 (2018).
pubmed: 29527499 doi: 10.1016/j.nicl.2017.12.028
Yeap, S. et al. Early visual sensory deficits as endophenotypes for schizophrenia: high-density electrical mapping in clinically unaffected first-degree relatives. Arch. Gen. Psychiatry 63, 1180–1188 (2006).
pubmed: 17088498 doi: 10.1001/archpsyc.63.11.1180
Schwartz, B. D., Maron, B. A., Evans, W. J. & Winstead, D. K. High velocity transient visual processing deficits diminish ability of patients with schizophrenia to recognize objects. Neuropsychiatry Neuropsychol. Behav. Neurol. 12, 170–177 (1999).
pubmed: 10456801
Schwartz, B. D., Maron, B. A., Evans, W. J. & Winstead, D. K. Smooth pursuit tracking deficits of patients with schizophrenia at specific within-sine wave bins. Neuropsychiatry Neuropsychol. Behav. Neurol. 12, 221–229 (1999).
pubmed: 10527106
Butler, P. D., Harkavy-Friedman, J. M., Amador, X. F. & Goman, J. M. Backward masking in schizophrenia: relationship to medication status, neuropsychological functioning, and dopamine metabolism. Biol. Psychiatry 40, 295–298 (1996).
pubmed: 8871777 doi: 10.1016/0006-3223(96)00007-8
Chen, Y. et al. Dependence of impaired eye tracking on deficient velocity discrimination in schizophrenia. Arch. Gen. Psychiatry 56, 155–161 (1999).
pubmed: 10025440 doi: 10.1001/archpsyc.56.2.155
Chen, Y., Nakayama, K., Levy, D. L., Mathysse, S. & Holzman, P. S. Psychophysical isolation of a motion-processing deficit in schizophrenics and their relatives and its association with impaired smooth pursuit. Pro. Natl Acad. Sci. USA 96, 4724–4729 (1999).
doi: 10.1073/pnas.96.8.4724
Green, M. F. & Nuechterlein, K. H. Backward masking performance as an indicator of vulnerability to schizophrenia. Acta Psychiatr. Scand. 99, 34–40 (1999).
doi: 10.1111/j.1600-0447.1999.tb05981.x
Mehta, N. & Cheng, H. Y. Micro-managing the circadian clock: the role of microRNAs in biological timekeeping. J. Mol. Biol. 425, 3609–3624 (2013).
pubmed: 23142644 doi: 10.1016/j.jmb.2012.10.022
Cheng, H. Y. et al. microRNA modulation of circadian-clock period and entrainment. Neuron 54, 813–829 (2007).
pubmed: 17553428 pmcid: 2590749 doi: 10.1016/j.neuron.2007.05.017

Auteurs

Ryo Saito (R)

Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Department of Biological Sciences, School of Science, The University of Tokyo, Tokyo, Japan.

Michinori Koebis (M)

Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Taku Nagai (T)

Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.

Kimiko Shimizu (K)

Department of Biological Sciences, School of Science, The University of Tokyo, Tokyo, Japan.

Jingzhu Liao (J)

Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.

Bolati Wulaer (B)

Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.

Yuki Sugaya (Y)

Department of Neurophysiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
International Research Center for Neurointelligence (WPI-IRCN), The University of Tokyo Institutes for Advanced study (UTIAS), The University of Tokyo, Tokyo, Japan.

Kenichiro Nagahama (K)

Department of Neurophysiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
International Research Center for Neurointelligence (WPI-IRCN), The University of Tokyo Institutes for Advanced study (UTIAS), The University of Tokyo, Tokyo, Japan.

Naofumi Uesaka (N)

Department of Neurophysiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
International Research Center for Neurointelligence (WPI-IRCN), The University of Tokyo Institutes for Advanced study (UTIAS), The University of Tokyo, Tokyo, Japan.

Itaru Kushima (I)

Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Medical Genomics Center, Nagoya University Hospital, Nagoya, Aichi, Japan.

Daisuke Mori (D)

Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.

Kazuaki Maruyama (K)

Department of Physiological Chemistry and Metabolism, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Kazuki Nakao (K)

Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Hiroki Kurihara (H)

Department of Physiological Chemistry and Metabolism, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Kiyofumi Yamada (K)

Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.

Masanobu Kano (M)

Department of Neurophysiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
International Research Center for Neurointelligence (WPI-IRCN), The University of Tokyo Institutes for Advanced study (UTIAS), The University of Tokyo, Tokyo, Japan.

Yoshitaka Fukada (Y)

Department of Biological Sciences, School of Science, The University of Tokyo, Tokyo, Japan.

Norio Ozaki (N)

Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.

Atsu Aiba (A)

Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. aiba@m.u-tokyo.ac.jp.
Department of Biological Sciences, School of Science, The University of Tokyo, Tokyo, Japan. aiba@m.u-tokyo.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH